Tetracyclines and Risk of Proliferative Vitreoretinopathy after Rhegmatogenous Retinal Detachment
Itay Nitzan1, Yossi Eshel1, Tehila Shlomov1
1Faculty of Medicine, Department of Ophthalmology, Hadassah-Hebrew University Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel.
Objective:
To evaluate the association between documented systemic tetracycline administration and the risk of proliferative vitreoretinopathy (PVR)-related outcomes after rhegmatogenous retinal detachment (RRD).
Design:
Retrospective cohort study with 1-year follow-up.
Participants:
Adults aged 18 years or older with RRD were identified within a multicenter federated electronic health record network. After 1:1 propensity score matching, 2886 patients with documented systemic tetracycline administration were compared with 2886 matched controls.
Methods:
Systemic tetracycline exposure was defined as a recorded prescription from 1 month before to 6 months after RRD-related cohort entry. Propensity score matching was performed on demographics, socioeconomic determinants, systemic and ophthalmic comorbidities, medications, laboratory values, and health care utilization. Time-to-event analyses were conducted using Kaplan-Meier estimation and Cox proportional hazards models. Prespecified sensitivity analyses and active comparator analyses were performed to assess robustness.
Main Outcome Measures:
Hazard ratios (HRs) for PVR-related outcomes, defined as complex retinal detachment repair, nondiabetic proliferative retinopathy, and tractional retinal detachment. Reoperation was evaluated as a secondary outcome.
Results:
Baseline characteristics were well balanced after matching. During comparable follow-up, systemic tetracycline administration was associated with a lower risk of complex retinal detachment repair (HR, 0.33; 95% confidence interval [CI], 0.25-0.43), nondiabetic proliferative retinopathy (HR, 0.63; 95% CI, 0.45-0.89), and tractional retinal detachment (HR, 0.57; 95% CI, 0.43-0.75). Reoperation was also less frequent among tetracycline-exposed patients (HR, 0.34; 95% CI, 0.26-0.46). Findings remained consistent across prespecified sensitivity analyses, including alternative exposure definitions, follow-up durations, doxycycline-only exposure, and active comparator analyses. E-values suggested robustness to unmeasured confounding, and positive and negative control outcomes supported the internal validity of the observed associations.
Conclusions:
Documented systemic tetracycline administration was associated with a lower risk of PVR-related outcomes after RRD. These findings support further prospective evaluation of tetracyclines as a potential adjunctive strategy for PVR prevention.
Financial Disclosure(S):
The authors have no proprietary or commercial interest in any materials discussed in this article.
